Exhibit 99.1

 

GRAPHIC

 

 

 

Contact:

Monique Greer

720-540-5268

mgreer@allos.com

 

Allos Therapeutics Reports Second Quarter 2011 Financial Results

 

- Second Quarter FOLOTYN® Net Product Sales Increased 39% Year-Over-Year -

 

- Allos to Merge with AMAG Pharmaceuticals to Create

Combined Company with Strengthened Commercial Portfolio and Improved Operating Leverage -

 

- Conference Call Scheduled for Today at 4:30 p.m. ET -

 

WESTMINSTER, Colo., August 4, 2011

— Allos Therapeutics, Inc. (Nasdaq: ALTH) today reported financial results for the second quarter ended June 30, 2011.

 

·                  FOLOTYN® (pralatrexate injection) net product sales increased 39% year-over-year to $11.0 million in the second quarter of 2011, compared to $7.9 million for the same period in 2010.

 

·                  As of June 30, 2011, the Company had no debt and $109.5 million in total cash, cash equivalents and investments.

 

“We’re enthusiastic about our planned merger with AMAG Pharmaceuticals, which will allow Allos stockholders to benefit from a combined organization with significantly improved operating leverage and a diversified portfolio of commercial products with overlapping customer bases,” said Paul L. Berns, president and chief executive officer of Allos Therapeutics.  “During the second quarter, we continued to build brand and disease state awareness for FOLOTYN in the U.S. for patients with relapsed or refractory PTCL while growing account penetration and optimizing the duration of treatment with FOLOTYN.  Along with growing U.S. sales of FOLOTYN for relapsed or refractory PTCL, our key objectives for the remainder of the year are to advance our global registration programs for FOLOTYN in first line PTCL and relapsed or refractory CTCL, and to expand the commercial potential of FOLOTYN outside the U.S. by pursuing regulatory approval in the EU, which may occur in early 2012.”

 

Financial Results

 

Net product sales for the second quarter of 2011 were $11.0 million, compared to $7.9 million for the same period in 2010, a 39% increase year-over-year.  Net product sales for the six months ended June 30, 2011 were $21.8 million, compared to $15.3 million for the same period in 2010, a 43% increase year-over-year.

 

In May 2011, Allos entered into a strategic collaboration agreement with Mundipharma

 

1


The following information was filed by Allos Therapeutics Inc (ALTH) on Thursday, August 4, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Allos Therapeutics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Allos Therapeutics Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account